OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Neurology is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)

Article	Citations
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	1639
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis	1595
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	1403
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	1105
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies	918
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study	842
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	776
Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	687
Stroke in China: advances and challenges in epidemiology, prevention, and management	593
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria	586
Small vessel disease: mechanisms and clinical implications	561
Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	526
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies	369
Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	368
An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models	341
The global burden of stroke: persistent and disabling	302
Global brain inflammation in stroke	291
Association between circadian rhythms and neurodegenerative diseases	262
Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016	261
CSF and blood biomarkers for Parkinson's disease	249
Frontotemporal dementia and its subtypes: a genome-wide association study	243
Gait impairments in Parkinson's disease	236
Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study	213
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study	212
Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study	208
Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-lev	208
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score	204
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial	196
Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study	195
Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study	191
Implications of sleep disturbance and inflammation for Alzheimer's disease dementia	176
Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications	176
Detection, risk factors, and functional consequences of cerebral microinfarcts	174
Migraine and the trigeminovascular system—40 years and counting	173
Traumatic brain injury in China	172
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications	161
Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial	161
Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project	159
An exoskeleton controlled by an epidural wireless brain–machine interface in a tetraplegic patient: a proof-of-concept demonstration	159
Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study	154
Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies	139
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study	137
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial	133
Therapeutic interventions in patients with prolonged disorders of consciousness	131
Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation	124
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial	123
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial	121
Association between pathological and MRI findings in multiple sclerosis	115
Global burden of traumatic brain and spinal cord injury	114
Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches	112
Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study	110
Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study	109
Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data	108
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis	108
Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies	106
Pathophysiology, prevention, and treatment of medication overuse headache	102
Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder	101
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial	100
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy	98
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study	98
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial	97
Stroke genetics: discovery, biology, and clinical applications	90
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders	86
Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomis	86
The genetic basis of DOORS syndrome: an exome-sequencing study	86
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial	85
Parkinson's disease in the Western Pacific Region	84
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders	84
MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers	79
Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study	79
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial	77
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator	75
Priorities to reduce the burden of stroke in Latin American countries	75
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial	73
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis	69
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial	66
The global burden of neurological disorders	65
Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data	65
Diagnosis, prognosis, and treatment of leukodystrophies	64
Management of epilepsy in women	61